1. Home
  2. PANW vs SNY Comparison

PANW vs SNY Comparison

Compare PANW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PANW
  • SNY
  • Stock Information
  • Founded
  • PANW 2005
  • SNY 1994
  • Country
  • PANW United States
  • SNY France
  • Employees
  • PANW N/A
  • SNY N/A
  • Industry
  • PANW Computer peripheral equipment
  • SNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • PANW Technology
  • SNY Health Care
  • Exchange
  • PANW Nasdaq
  • SNY Nasdaq
  • Market Cap
  • PANW 124.9B
  • SNY 116.1B
  • IPO Year
  • PANW 2012
  • SNY N/A
  • Fundamental
  • Price
  • PANW $215.31
  • SNY $48.72
  • Analyst Decision
  • PANW Buy
  • SNY Buy
  • Analyst Count
  • PANW 45
  • SNY 4
  • Target Price
  • PANW $213.77
  • SNY $61.50
  • AVG Volume (30 Days)
  • PANW 5.6M
  • SNY 4.0M
  • Earning Date
  • PANW 11-19-2025
  • SNY 10-24-2025
  • Dividend Yield
  • PANW N/A
  • SNY 3.28%
  • EPS Growth
  • PANW N/A
  • SNY 118.56
  • EPS
  • PANW 1.60
  • SNY 8.65
  • Revenue
  • PANW $9,221,500,000.00
  • SNY $53,714,621,258.00
  • Revenue This Year
  • PANW $16.29
  • SNY $1.40
  • Revenue Next Year
  • PANW $13.43
  • SNY $6.67
  • P/E Ratio
  • PANW $136.11
  • SNY $5.64
  • Revenue Growth
  • PANW 14.87
  • SNY 15.65
  • 52 Week Low
  • PANW $144.15
  • SNY $44.62
  • 52 Week High
  • PANW $217.91
  • SNY $60.12
  • Technical
  • Relative Strength Index (RSI)
  • PANW 68.73
  • SNY 52.94
  • Support Level
  • PANW $208.32
  • SNY $44.62
  • Resistance Level
  • PANW $209.51
  • SNY $51.05
  • Average True Range (ATR)
  • PANW 4.63
  • SNY 0.83
  • MACD
  • PANW 0.67
  • SNY 0.28
  • Stochastic Oscillator
  • PANW 88.88
  • SNY 63.83

About PANW Palo Alto Networks Inc.

Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: